The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis
Author:
Affiliation:
1. Department of Hematology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China
2. Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China
Funder
“333 Projects”Foundation of Jiangsu Province
Science and Technology Development Fund of Huai’an City
“533 Projects” Foundation of Huai’an City
Publisher
Informa UK Limited
Subject
Hematology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/09537104.2019.1624706
Reference35 articles.
1. Pathogenesis of immune thrombocytopenia
2. Can Immune Thrombocytopenia Be Cured with Medical Therapy?
3. Clinical updates in adult immune thrombocytopenia
4. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment of Immune Thrombocytopenia: Contextualization from a Historical Perspective;Hematology Reports;2024-06-26
2. Clinical efficacy of two different doses of rituximab as a treatment option in adult patients with chronic immune thrombocytopenia;The Egyptian Journal of Internal Medicine;2024-06-11
3. Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study;The Lancet Regional Health - Western Pacific;2024-06
4. Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials;Thrombosis Research;2024-03
5. Successful treatment pure red cell aplasia after ABO major mismatched allogeneic hematopoietic stem cell transplantation with avatrombopag and low dose rituximab;Transfusion;2024-02-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3